Key facts
- Eikonizo Therapeutics’s last known valuation is $54.0M (Dec 2023).
- It has raised $46.1M across 2 recorded rounds; the latest was Seed Round ($371K) in May 2018.
- Notable investors include National Institutes of Health, F-Prime Capital, Johnson & Johnson Innovation - JLABS, Mission BioCapital, Alzheimers Drug Discovery Foundation — 8 tracked in total.
- Eikonizo Therapeutics has filed 2 Form Ds with the SEC, most recently May 2018 ($371K sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Eikonizo Therapeutics
Funding rounds
2 roundsAbout Eikonizo Therapeutics
Developer of brain-penetrant and peripherally-restricted small molecules designed to slow or modify the progression of neurodegenerative and cardiorenal diseases. The company offers selective HDAC6 inhibitors, dual-action intracellular transport and proteostasis modulation, and mitigation of protein aggregation, enabling patients and healthcare providers to improve cellular health, preserve nerve function, and potentially delay disease onset.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2017
- Employees
- 10
- Website
- eikonizo.com/
- Ownership
- Privately Held (backing)
Eikonizo Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Eikonizo Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Eikonizo Therapeutics in its N-PORT filings yet. We sweep new filings monthly.